Owners, management and financials
CVR: 30082346
Secondary names: Heslet Pharma A/S, TRIFOILIUM A/S
Previous names: WYSPA ApS, TRIFOILIUM ApS, REPONEX PHARMACEUTICALS ApS
DKK 0
Gross profit
Net result: DKK -6,570,000
Pharma Equity Group A/S (100%)
CVR · view owners
Christian Henrik Tange
Board: Christian Vinding Thomsen (chair) and 2 members
CVR · view management
Active
Founded 4 December 2006
CVR · view overview
1 employee
CVR · 2018
Director registered: Christian Henrik Tange
CVR · 19/12/2025
View the full event history
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.
Selskabets formål er at drive virksomhed med at udvikle lægemidler samt dermed beslægtede aktiviteter og at være Holding virksomhed for selskaber med tilsvaren-de formål.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 0 | -6.6 mio. | 7.3 mio. | 4.6 mio. | - | |
| 202401/01/2024 – 31/12/2024 | 0 | -11.9 mio. | 3.6 mio. | -8.8 mio. | - | |
| 202301/01/2023 – 31/12/2023 | 0 EUR | -14.3 mio. EUR | 21.7 mio. EUR | 16.8 mio. EUR | - | |
| 202201/01/2022 – 31/12/2022 | - | -10.2 mio. | 20 mio. | 17.4 mio. | - | |
| 202101/01/2021 – 31/12/2021 | 0 | -9.9 mio. | 28.7 mio. | 27.4 mio. | - | |
| 202001/01/2020 – 31/12/2020 | 0 | -1.5 mio. | 20.4 mio. | 13.4 mio. | - | |
| 201901/01/2019 – 31/12/2019 | 0 | -1.9 mio. | 17.5 mio. | 14.9 mio. | - | |
| 201801/01/2018 – 31/12/2018 | 0 | -1.3 mio. | 9.7 mio. | 2.4 mio. | - | |
| 201701/01/2017 – 31/12/2017 | - | -1.6 mio. | 7.9 mio. | 3.7 mio. | - | |
| 201601/01/2016 – 31/12/2016 | - | -332 t. | 7.9 mio. | 5.2 mio. | - | |
| 201501/01/2015 – 31/12/2015 | - | -934 t. | 2.9 mio. | 536 t. | - | |
| 201401/01/2014 – 31/12/2014 | 1 | -683 t. | 3.1 mio. | 1.5 mio. | - | |
| 201301/01/2013 – 31/12/2013 | - | 150 t. | 2 mio. | 230 t. | - | |
| 201201/01/2012 – 31/12/2012 | - | -18 t. | 940 t. | 80 t. | - |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of REPONEX PHARMACEUTICALS A/S is 30082346.
REPONEX PHARMACEUTICALS A/S is owned by Pharma Equity Group A/S.
The management of REPONEX PHARMACEUTICALS A/S consists of Christian Henrik Tange.
The board of REPONEX PHARMACEUTICALS A/S consists of Christian Vinding Thomsen, Troels Peter Troelsen and Charlotte Pahl, with Christian Vinding Thomsen as chair.
In 2025, REPONEX PHARMACEUTICALS A/S reported a gross profit of DKK 0.
REPONEX PHARMACEUTICALS A/S had 1 employee in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2025. Revenue came to DKK 0, and the net result was DKK -6,570,000.
Address changed to Slotsmarken 12 1. th 12, 1 th, 2970 Hørsholm (January 26, 2026).
Contact info changed: new website: www.reponex.dk (January 26, 2026).
As of December 19, 2025, Christian Henrik Tange is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of December 19, 2025, Sebastian Bo Jakobsen has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of August 12, 2025, BDO Statsautoriseret Revisionspartnerselskab has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of August 12, 2025, BDO Holding VII, statsautoriseret revisionsaktieselskab has stepped down as auditor of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK -11,943,000.
As of April 1, 2025, Sebastian Bo Jakobsen is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of April 1, 2025, Thomas Kaas Selsø has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -14,346,000.
As of June 15, 2023, Peter Mørch Eriksen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 14, 2023, Thomas Kaas Selsø is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of June 14, 2023, Sigbjørn Georg Nielsen Kjærgård has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of June 13, 2023, Thomas Kaas Selsø has stepped down as director of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2022. The net result was DKK -10,209,830.
As of April 27, 2023, BDO Holding VII, statsautoriseret revisionsaktieselskab has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of April 27, 2023, Grant Thornton, Godkendt Revisionspartnerselskab has stepped down as auditor of REPONEX PHARMACEUTICALS A/S.
As of April 27, 2023, Lisbeth Thyregod has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of April 27, 2023, Mette Zacho has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of March 31, 2023, Peter Mørch Eriksen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of March 31, 2023, Mette Zacho has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of March 31, 2023, Sigbjørn Georg Nielsen Kjærgård has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of March 24, 2023, Pharma Equity Group A/S is registered as an owner of REPONEX PHARMACEUTICALS A/S with an ownership share of 100%.
As of October 11, 2022, Christian Vinding Thomsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of October 11, 2022, Sigbjørn Georg Nielsen Kjærgård has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of October 11, 2022, Sigbjørn Georg Nielsen Kjærgård is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of October 11, 2022, Klaus Snej Jensen has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of October 10, 2022, Christian Vinding Thomsen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of October 10, 2022, Sigbjørn Georg Nielsen Kjærgård has left the board of directors of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -9,883,156.
As of March 1, 2022, Thomas Kaas Selsø is registered as director of REPONEX PHARMACEUTICALS A/S.
As of October 14, 2021, Katrine Hoff Schlichtkrull has left the board of directors of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -1,504,899.
As of June 22, 2021, Troels Peter Troelsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 22, 2021, Katrine Hoff Schlichtkrull has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 22, 2021, Christian Vinding Thomsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 21, 2021, Troels Peter Troelsen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of March 1, 2021, Klaus Snej Jensen is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of March 1, 2021, Torsten Bjørn has stepped down as director of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2019. Revenue came to DKK 0, and the net result was DKK -1,853,921.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2018. Revenue came to DKK 0, and the net result was DKK -1,256,682.
As of June 17, 2019, Troels Peter Troelsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 17, 2019, Sigbjørn Georg Nielsen Kjærgård has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 17, 2019, Henrik Bulskov has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 16, 2019, Troels Peter Troelsen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2017. Gross profit came to DKK -1,266,822, and the net result was DKK -1,576,249.
As of May 14, 2018, Charlotte Pahl has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
On May 14, 2018, the company changed its name from REPONEX PHARMACEUTICALS ApS to REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2016. Gross profit came to DKK 241,832, and the net result was DKK -331,569.
As of May 31, 2017, Lisbeth Thyregod has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 25, 2016, Erik Lennard Vitting Skovbjerg has left the board of directors of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2015. Gross profit came to DKK -1,182,333, and the net result was DKK -933,677.
As of June 21, 2016, Troels Peter Troelsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 21, 2016, Erik Lennard Vitting Skovbjerg has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 20, 2016, Troels Peter Troelsen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of April 19, 2016, Torsten Bjørn is registered as director of REPONEX PHARMACEUTICALS A/S.
As of April 19, 2016, Henrik Lasse Lindblad has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of October 30, 2015, Jacob Rosenberg has left the board of directors of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2014. Revenue came to DKK 1, and the net result was DKK -682,835.
As of March 17, 2015, Troels Peter Troelsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of March 17, 2015, Jacob Rosenberg has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of March 17, 2015, Henrik Bulskov has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
On November 12, 2014, the company changed its name from TRIFOILIUM ApS to REPONEX PHARMACEUTICALS ApS.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2013. The net result was DKK 149,866.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2012. The net result was DKK -17,837.
As of February 15, 2012, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of February 15, 2012, DKNF 387 ApS has stepped down as auditor of REPONEX PHARMACEUTICALS A/S.
On May 17, 2011, the company changed its name from WYSPA ApS to TRIFOILIUM ApS.
As of February 2, 2010, Henrik Lasse Lindblad is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of February 2, 2010, Michael Secher has stepped down as director of REPONEX PHARMACEUTICALS A/S.
As of December 31, 2008, DKNF 387 ApS has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of December 31, 2008, RevisionsFirmaet Edelbo og Lund-Larsen I/S has stepped down as auditor of REPONEX PHARMACEUTICALS A/S.
As of December 31, 2008, Michael Secher is registered as director of REPONEX PHARMACEUTICALS A/S.
As of December 31, 2008, Jon Steffen Therkildsen has stepped down as director of REPONEX PHARMACEUTICALS A/S.
As of October 1, 2007, RevisionsFirmaet Edelbo og Lund-Larsen I/S has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of October 1, 2007, REVISOR ERIK LUND-LARSEN has stepped down as auditor of REPONEX PHARMACEUTICALS A/S.
As of May 15, 2007, Jon Steffen Therkildsen is registered as director of REPONEX PHARMACEUTICALS A/S.
As of May 15, 2007, Mikael Thiesen has stepped down as director of REPONEX PHARMACEUTICALS A/S.
As of December 4, 2006, REVISOR ERIK LUND-LARSEN has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of December 4, 2006, Mikael Thiesen is registered as director of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S was founded on December 4, 2006.
Companies in the same industry and area
CVR 36494433
CVR 37509736
CVR 39161672
CVR 41489189
CVR 44807866
